{'fraction_non_alphanumeric': 0.02107481559536354, 'fraction_numerical': 0.006322444678609062, 'mean_word_length': 6.037037037037037, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Post‐Konyne Hepatitis: The Ineffectiveness of Screening for the Hepatitis B Antigen (HBAg)

Sixteen patients who received Konyne for bleeding episodes or for hemostasis during surgical procedures were evaluated for signs of posttransfusion hepatitis. Four patients died from their primary disease. Of the remaining 12 patients at risk, six patients developed posttransfusion hepatitis. Sera from four of the six patients with hepatitis were positive for the hepatitis B antigen (HBAg). Aliquots of Konyne from the specific lot (K4797) implicated in three cases of HBAg‐positive hepatitis were negative for HBAg by immunodiffusion, immunoelectroosmophoresis, and radioimmunoassay. The high incidence of hepatitis associated with Konyne considerably limits the use for this specialized coagulation factor concentrate. HBAg screening by available technics does not necessarily detect Konyne preparations capable of transmitting HBAg‐positive hepatitis.